Neurol. praxi. 2007;8(4):226-230

Současný stav a perspektivy trombolytické terapie (část I.)

MUDr. David Goldemund, MUDr. Robert Mikulík, MUDr. Michal Reif
I. neurologická klinika LF MU a FN u sv. Anny Brno

Hlavním cílem te­rapie akutního mozkového infarktu je včasná rekanalizace uzavřené mozkové tepny. Standardní terapií v časovém okně do tří hodin od vzniku příznaků je intravenózní trombolýza. Aktuální výzkum se soustřeďuje jednak na dosažení vyššího procenta rekanalizací (akcelerovaná trombolýza, intervenční techniky), jednak na selekci kandidátů vhodných k trombolýze i po uplynutí 3 hodinového časového okna.

První část textu se bude zabývat intravenózní, intraarteriální a kombinovanou trombolýzou. V druhé části budou probrány novější terapeutické postupy jako je sonotrombolýza, mechanická rekanalizace a využití nových trombolytik či protidestičkových preparátů. V závěru druhé části bude také uveden stručný přehled v současnosti akceptovaných a schválených postupů specifické terapie akutního iktu s ohledem na dobu trvání příznaků.

Keywords: akutní mozkový infarkt, kombinovaná trombolýza, sonotrombolýza, embolektomie

Published: November 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goldemund D, Mikulík R, Reif M. Současný stav a perspektivy trombolytické terapie (část I.). Neurol. praxi. 2007;8(4):226-230.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adams HP, Jr. et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, 2007. 38(5): p. 1655-1711. Go to original source... Go to PubMed...
    2. Albers GW et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol; 2006, 60(5): 508-517. Go to original source... Go to PubMed...
    3. Barnwell SL et al. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR Am J Neuroradiol; 1994, 15(10):1817-1822.
    4. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke; 2004,35(4): 904-911. Go to PubMed...
    5. Furlan AJ, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke; 2006, 37(5): 1227-1231. Go to original source... Go to PubMed...
    6. Furlan A et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama; 1999, 282(21): 2003-2011. Go to original source... Go to PubMed...
    7. Hacke W et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet; 2004, 363(9411): p. 768-774. Go to original source... Go to PubMed...
    8. Hacke W et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet; 1998. 352(9136): p. 1245-1251. Go to original source... Go to PubMed...
    9. Hacke W, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke; 2005. 36(1): 66-73. Go to original source... Go to PubMed...
    10. Hacke W et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology; 1999. 53(7 Suppl 4): S3-S14.
    11. Lopez AD and CD. Mathers, Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol; 2006. 100(5-6): p. 481-499. Go to original source... Go to PubMed...
    12. Mikulik R et al. Accuracy of serial National Institutes of Health Stroke Scale scores to identify artery status in acute ischemic stroke. Circulation; 2007. 115(20): p. 2660-2665. Go to original source... Go to PubMed...
    13. Smith WS, Safety of mechanical thrombectomy and intravenous tissue plasmiogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removaln in Cerebral Ischemia (merci) trial, part I. AJNR Am J Neuroradiol, 2006. 27(6): p. 1177-1182.
    14. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med, 1995, 333(24): p. 1581-1587.
    15. Zeumer H et al. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology; 1993, 35(2): 159-162. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.